Contract Manufacturing Solutions

Aragen Bioscience delivers end-to-end biologics solutions, transforming complex R&D challenges into high-value outcomes. With nearly 30 years of experience, Aragen offers royalty-free cell line development, scalable bioproduction, antibody discovery, and advanced analytics. Our biologics development se...

Chemical Development Solutions provides a convenient, single-site distribution of infrastructure, thereby delivering a seamless and innovative transition of solutions from lab to pilot plant and bulk manufacturing, with speed and quality.

We ensure quality in the process during the design an...

Aragen Life Sciences offers a range of Formulation R&D solutions that include pre-formulation studies, formulation development, analytical R&D, reformulation and stability studies. We can also support clinical supplies and manufacturing of exhibit batches in collaboration with our partners and offe...

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035, driving global pharma innovation: BCG-IPSO Report

Case Study

Aragen Life Sciences expands its operations from Hyderabad

Brochure

Aragen Commission state-of-the-art Formulations Manufacturing Facility in Hyderabad, India

An optimal upstream process development approach to increase the titers of the monoclonal antibodies (mAbs)

Aragen appoints Dr. Manjunath Ramarao as Chief Scientific Officer and Executive Vice President, Integrated Drug Discovery; Jayadeva Sajankila as Vice President and Head, Chemical Development Solutions

Capabilities

Aragen Bioscience Validates Getinge's Single-Use Production Reactor (SUPR)

Capabilities

Aragen operationalizes first phase of its Biologics manufacturing facility in India

Your Fast Track to IND

Aragen setting up a $ 30 million bio-manufacturing site in India

500+ Clinical and Commercial Programs Delivered

Aragen strengthens Discovery leadership with the appointment of Neeraj Garg as CEO of its Discovery Solutions business

Contract Manufacturing Solutions

FAR Biotech and Aragen Life Sciences Enter into a Collaboration to Advance Preclinical Program in Neurodegeneration

Aragen will provide integrated drug discovery (IDD) services to support FAR Biotech’s AI-driven, quantum biomodelling approach

Unlock Innovation with Design of Experiments (DoE)/RFT Approach

DHL Express India and Aragen LifeSciences sign GoGreen Plus partnership to reduce carbon emissions

GoGreen Plus uses sustainable aviation fuel (SAF) to enable customers to reduce Scope 3 emissions

Analytical Solutions at Aragen

Aragen secures $100 Mn investment from Quadria Capital; Quadria acquires minority stake in the Company

Investment will fund expansion to meet rising demand for CRDMO services

Formulation Solutions Development & Clinical Manufacturing for Challenging NCEs

CSIR-IICT, Aragen and Kewaunee sign MOU for offering “Finishing School” skill program to postgraduate students in Chemistry

Focus on developing talent in the areas of Synthetic Organic Chemistry and Analytical Chemistry

Unparalleled Efficiency and Precision in HPAPI Development and Manufacturing

Aragen Life Sciences receives Science Based Targets initiative (SBTi) approval for its greenhouse gas emission reduction targets

Process Development Services

Aragen Life Sciences Ltd. receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for Pioneering Excellence in Drug Discovery and Development Services

Resin Recycling Studies

6th August, 2025; Hyderabad, India, Aragen, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the appointment of Aniel Khubchandani as CEO of its Development & Manufacturing Solutions business. Aniel will be a member of Aragen’s Management Council and will be based in Hyderabad. 

8th January, 2025: Hyderabad: Aragen Life Sciences, a globally renowned Contract Research, Development and Manufacturing Organization (CRDMO), has received the prestigious Platinum Medal rating from EcoVadis. This highest level of recognition places Aragen in the top 1% of companies worldwide for its exemplary sustainability practices. 

12 June, 2025 – Morgan Hill, California: Aragen, a leading contract research, development and manufacturing organization (CRDMO), announced that it will commence GMP manufacturing at its biologics manufacturing facility in Bangalore, India from late July 2025.  Aragen has successfully completed the facility and equipment qualification and demonstrated the productivity of its intensified fed batch cell culture manufacturing platform to deliver titers >25 g/L.

Aragen Life Sciences Limited (“Aragen”), a global contract research, development, and manufacturing organization (CRDMO), today announced the appointment of Dr. Subodh Deshmukh as CEO of Aragen Bioscience and President of Development Services. Dr. Deshmukh joins Aragen from Zymergen, USA where he was the Chief Development Officer and will be based in the Morgan Hill, California campus of Aragen. Aragen Bioscience is the US-subsidiary of Aragen and provides research and development services for biologics.

Aragen Life Sciences Private Limited (“Aragen”), a global contract research, development, and manufacturing organization (CRDMO) announces a collaboration with Azurity Pharmaceuticals Inc, a US-based pharmaceutical company focused on developing innovative dose-forms and formulations of products to serve the needs of overlooked patients. The agreement is for a dedicated pharmaceuticals formulations development center at Aragen’s Hyderabad campus. The dedicated center will support the development of multiple products across a wide range of therapeutic areas. 

In this series of interviews, we speak to the teams behind the winning concepts at CPHI Pharma Awards 2022, in each of the different categories, from digital innovation to CEO of the year. 

It’s undoubtedly a very interesting time for the global Contract Research Organisation (CRO) industry. This is particularly true for CROs with locations across the world who have been able to leverage the talent available globally to support their customers’ projects.

How confident are you in your ability to reach appropriate titers for an unknown biologic?

This question is at the heart of decision-making when choosing a cell line development (CLD) platform. When pharmaceutical sponsors have the ability to do so, testing multiple platforms to determine which will produce optimal titers provides process insight and mitigates risk. However, platform testing requires sponsors and their partners to balance timelines against the amount of parallel work, arriving at a data-supported resolution as quickly as possible.

In many cases, vendors overpromise and underdeliver. For example, a vendor may promise a three-month timeline to a research cell bank (RCB) but provide scant details on how that timeline is achieved. A sponsor’s only recourse — most of the time — is to find a forthcoming and knowledgeable vendor that can provide insight intowhya given timeline may be unrealistic, a budget may be miscalculated, or a cost of goods sold (COGS) may be overly optimistic.

These key metrics are influenced by numerous factors, from the available technology to regulators’ expectations for Phase I. Moreover, even a seemingly well-developed cell line can be viable for Phase 1, but end up being inadequate for commercialization (i.e., it does not scale well or its quality is inconsistent). Some organizations even opt to rush to Phase 1, fully understanding they will need to switch lines before commercialization. In either case, a comparability study between Phase 1 and, ultimately, Phase III, is expensive and time-consuming.

How has the sector of R&D applications and discovery evolved over the years and what are the strategies utilized by your company to stay competitive?

Aragen Life Sciences (formerly, GVK Biosciences), stated that it expects the demand for outsourced research, development and manufacturing services to continue to pick pace.

With rising demand for integrated end-to-end services, the CRO (contract research organisation)/CDMO (contract development and manufacturing) industry will see increasing consolidation both at the global level as well as in India, said Manni Kantipudi, CEO, Aragen Life Sciences.

In a quest to understand how companies are looking to buck up their talent acquisition game when it comes to R&D, ETHRWorld spoke with Suresh Anubolu, Chief Human Resources Officer at Aragen Life Sciences.

Development in the scientific advancements have brought brilliant growth and career opportunities in the life science domain. Hence, it is more than in-depth research and study. The domain has immense career opportunities for individuals who are passionate about science.

The CDMO's services will help to advance clinical testing of Clearmind's drug candidate for treating alcohol use disorder

Aragen Life Sciences (formerly GVK BIO), a leading Contract Research and Development Organization, headquartered out of Hyderabad, India, announces an expansion of their discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.

Aragen Life Sciences (formerly, GVK BIO), a leading Contract Research and Development Organization (CRDO), headquartered out of Hyderabad, India, announced a strategic partnership with FMC Corporation, a global leader in innovative agricultural science, that provides solutions towards crop protection, plant health, and professional pest and turf management.

“There is little interest in setting up new labs with large footprints that cost both time and money: the focus is on speed while levering service providers that have both competence and scale.

Aragen Life Sciences (Aragen), formerly known as GVK Biosciences and a leading contract research, development and manufacturing organization, officially marked its transition to a new brand identity. With a legacy of over 20 years of partnering with innovator life sciences companies around the world, Aragen is poised for growth in the outsourced discovery, developmen...

We expect India to benefit from the expected growth in needs for API: Ramesh Subramanian, CCO, Aragen

Aragen Life Sciences (“Aragen”), formerly known as GVK Biosciences and a leading contract research organization (CRO), announced today that Goldman Sachs, an active investor in India, has taken a significant minority stake in the company by acquiring shares previously held by ChrysCapital and other existing shareholders.